Hypothyroidism evaluation after radiotherapy of breast and supraclavicular in patients with breast cancer

Karimijavid, Mohammad R; S Pashaki, Abdolazim; Borzouei, Shiva; Khanlarzadeh, Elham; Gholami, Mohammad H; Nikzad, Safoora

Hypothyroidism evaluation after radiotherapy of breast and supraclavicular in patients with breast cancer

Authors

¹ Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

² Department of Radiooncology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

³ Clinical Research Development Unit, Shahid Beheshti Hospital, Hamadan University of Medical Science, Hamadan, Iran

⁴ Department of Community Medicine, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

⁵ Mahdieh Radiotherapy and Brachytherapy Charitable Center, Hamadan, Iran

⁶ Department of Medical Physics, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

Abstract

Background: This study aims to evaluate the risk of hypothyroidism (HT) after radiotherapy (RT) of breast and supraclavicular in patients with breast cancer (BC).
Materials and Methods: In a historical cohort study, the records of all patients with BC who had been referred to the Mahdieh radiotherapy Center of Hamadan from 2017 to 2019 were reviewed. Demographic characteristics, clinical information, previous and current used treatment methods (surgery, radiotherapy, chemotherapy), number of RT sessions and doses, and HT (TSH >5 mIU/L) were extracted from the patient's documents. Data were analyzed using SPSS software version 16.
Results: Out of 304 patients referred to the Center, 266 patients were investigated. The mean TSH was 6.3 ± 7.9 ml/L (1.5 to 65.4). Approximately half of the patients were in Stage 2 of the disease. 37 (16.4%) patients were diagnosed with HT, of which 8.8% were clinical, and 7.5% were subclinical. The mean total dose of HT patients (5621.62 ± 491.67) was significantly higher than other patients (5304.76 ± 937.98). 21 patients (56.8%) in Stage 3 and 4 and 16 (43.2%) patients in Stages 1 and 2 had HT (P = 0.006). Spearman correlation coefficient showed that there was a significant relationship between total dose and TSH hormone (r = 0.624), the number of RT sessions with TSH hormone (r = 0.237), and total dose with T4 hormone (r = -0.232).
Conclusion: The findings of this study showed that the risk of HT increases significantly in patients with BC who undergo RT of breast and supraclavicular. Patients with higher stage, more radiation, and more RT sessions are at higher risk of HT.

Keywords

References

1.	Pesch AM, Pierce LJ, Speers CW. Modulating the radiation response for improved outcomes in breast cancer. JCO Precis Oncol 2021;5:PO.20.00297.
2.	Shah C, Al-Hilli Z, Vicini F. Advances in breast cancer radiotherapy: Implications for current and future practice. JCO Oncol Pract 2021;17:697-706.
3.	Kanyilmaz G, Aktan M, Koc M, Demir H, Demir LS. Radiation-induced hypothyroidism in patients with breast cancer: A retrospective analysis of 243 cases. Med Dosim 2017;42:190-6.
4.	Voutsadakis IA. The TSH/Thyroid hormones axis and breast cancer. J Clin Med 2022;11:687.
5.	Ilic L, Haidinger G, Simon J, Hackl M, Schernhammer E, Papantoniou K. Trends in female breast cancer incidence, mortality, and survival in Austria, with focus on age, stage, and birth cohorts (1983-2017). Sci Rep 2022;12:7048.
6.	Mirsadraei M, Seilanian Toosi M, Mohebbi S, Khalili-Hezarjaribi H. Evaluating dose to thyroid gland in women with breast cancer during radiotherapy with different radiation energies at supraclavicular fossa region. J Radiother Pract 2018;17:373-6.
7.	Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J Natl Cancer Inst 2014;106:dju289.
8.	Khan NF, Mant D, Carpenter L, Forman D, Rose PW. Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: A database study. Br J Cancer 2011;105(Suppl 1):S29-37.
9.	Smith GL, Smith BD, Giordano SH, Shih YC, Woodward WA, Strom EA, et al. Risk of hypothyroidism in older breast cancer patients treated with radiation. Cancer 2008;112:1371-9.
10.	De Groot S, Janssen LG, Charehbili A, Dijkgraaf EM, Smit VT, Kessels LW, et al. Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: Results from the NEOZOTAC trial (BOOG 2010-01). Breast Cancer Res Treat 2015;149:461-6.
11.	Akyurek S, Babalıoğlu İ, Köse K, Gokce S. Thyroid dysfunction following supraclavicular irradiation in the management of carcinoma of the breast. Int J Hematol Oncol 2014;2:139-144.
12.	Tunio MA, Al Asiri M, Bayoumi Y, Stanciu LG, Al Johani N, Al Saeed EF. Is thyroid gland an organ at risk in breast cancer patients treated with locoregional radiotherapy? Results of a pilot study. J Cancer Res Ther 2015;11:684-9.
13.	Park J, Kim C, Ki Y, Kim W, Nam J, Kim D, Park D, et al. Incidence of hypothyroidism after treatment for breast cancer: A Korean population-based study. PLoS One 2022;17:e0269893.
14.	Falstie-Jensen AM, Esen BÖ, Kjærsgaard A, Lorenzen EL, Jensen JD, Reinertsen KV, et al. Incidence of hypothyroidism after treatment for breast cancer-a Danish matched cohort study. Breast Cancer Res 2020;22:106.
15.	Pillai US, Kayal S, Cyriac S, Nisha Y, Dharanipragada K, Kamalanathan SK, et al. Late effects of breast cancer treatment and outcome after corrective interventions. Asian Pac J Cancer Prev 2019;20:2673-9.
16.	Reinertsen KV, Cvancarova M, Wist E, Bjoro T, Dahl AA, Danielsen T, et al. Thyroid function in women after multimodal treatment for breast cancer stage II/III: Comparison with controls from a population sample. Int J Radiat Oncol Biol Physics 2009;75:764-70.
17.	Akgun Z, Atasoy BM, Ozen Z, Yavuz D, Gulluoglu B, Sengoz M, et al. V30 as a predictor for radiation-induced hypothyroidism: A dosimetric analysis in patients who received radiotherapy to the neck. Radiat Oncol 2014;9:104.
18.	Wei S, Tao N, Ouyang S, Liu T, Guo Q, Tao F, et al. Dosimetric comparisons of intensity-modulated radiation therapy and three-dimensional conformal radiation therapy for left-sided breast cancer after radical surgery. Prec Radiat Oncol 2019;3:80-6.
19.	McGowan DR, Pratt BE, Hinton PJ, Peet DJ, Crawley MT. Iodine-131 monitoring in sewage plant outflow. J Radiol Prot 2014;34:1-14.

Advanced Biomedical Research